CRLQT76Charles River Laboratories International, Inc.·NYSE
338.54-5.81%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E—EPS (ttm)-4.85Insider Own1.51%Shs Outstand48.17MPerf Week-5.24%
Market Cap16.31BForward P/E26.46EPS next Y12.80Insider Trans-26.54%Shs Float47.20MPerf Month16.66%
Enterprise Value19.14BPEG—EPS next Q2.97Short Float6.00%Perf Quarter44.60%
Income-239.00MP/S4.08EPS this Y11.11%Short Ratio2.98Perf Half Y96.46%
Sales4.00BP/B5.73EPS next Y12.45%ROA-3.17%Short Interest2.83MPerf YTD69.71%
Book/sh59.09P/C84.93EPS next 5Y11.60%ROE-7.72%52W High379.63 -10.82%Perf Year89.01%
Cash/sh3.99P/FCF43.95EPS past 3/5Y—ROIC7.72%52W Low146.20 131.56%Perf 3Y93.37%
Dividend Est.—EV/EBITDA86.62Sales past 3/5Y0.33% 6.55%Gross Margin32.24%Volatility5.04% 4.81%Perf 5Y-20.12%
Dividend TTM—EV/Sales4.79EPS Y/Y TTM—Oper. Margin12.35%ATR (14)15.41Perf 10Y312.20%
Dividend Ex-Date—Quick Ratio1.04Sales Y/Y TTM-0.74%Profit Margin-5.96%RSI (14)56.21Recom2.24
Dividend Gr. 3/5Y—Current Ratio1.35EPS Q/Q-3.21%SMA203.79%Beta1.32Target Price308.36
Payout0.00%Debt/Eq1.06Sales Q/Q-2.71%SMA5011.81%Rel Volume1.53Prev Close359.41
Employees19,000LT Debt/Eq1.06EarningsNov 04SMA20052.25%Avg Volume1.05MPrice338.54
IPO DateJun 23, 2000Option/ShortYes / YesEPS/Sales Surpr.10.14% 2.75%Net Debt/EBITDA12.83Volume1,604,507Change-5.81%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-30-26ResumedUBSNeutral$357
Sep-28-26ReiteratedJefferiesBuy$195 → $340
Sep-25-26ReiteratedRobert W. Baird$291 → $334
Sep-25-26ReiteratedEvercore ISI GroupOutperform$320 → $330
Sep-25-26ReiteratedDeutsche BankBuy$240 → $320
Sep-25-26ReiteratedMizuhoNeutral$264 → $295
Sep-25-26ReiteratedBarclaysOverweight$300 → $330
Sep-25-26ReiteratedRBC CapitalOutperform$282 → $322
Sep-17-26ReiteratedArgus ResearchHold$250 → $330
Sep-11-26ReiteratedEvercore ISI GroupOutperform$220 → $320
Latest News· Times ET
Nov-02-26
Oct-29-26
Oct-28-26
Oct-27-26
Oct-26-26
Oct-26-2612:10PM
Oct-22-26
Oct-15-26
Oct-14-26
Oct-13-26
Oct-09-26
Oct-07-26
Company

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/27/2025
FY 2024
12/28/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,9994,0154,0504,129—————
Cost of Goods Sold Incl. D&A2,7102,7902,7182,627—————
Gross Profit1,2891,2261,3321,503—————
Selling, General and Administrative Excl. Other754743751748—————
Research and Development
0000—————
Other Operating Expense41-25353137—————
Operating Income494508227617—————
Interest Expense106107126137—————
Unusual Expense
—————————
Non-Operating Income (Expense)-571-500-8101—————
Net Income Before Taxes-184-10093581—————
Income Taxes534368101—————
Consolidated Net Income-239-14410475—————
Net Income From Continuing Operations-236-14225480—————
Net Income-239-14410475—————
EPS (Recurring)-4.84-2.910.209.27—————
EPS (Basic, Before Extraordinaries)-4.84-2.910.209.27—————
EPS (Diluted)-4.85-2.910.209.22—————
EBITDA2214115811,032—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——930.8025.64—————
Price To Sales Ratio4.062.542.342.92—————
Gross Margin32.2330.5432.8936.40—————
Operating Margin12.3512.655.6014.94—————
Net Margin-5.98-3.590.2511.50—————
Shares Outstanding48505151—————
Market Capitalization16,25010,1839,49412,056—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$410.68$335.76$260.84$185.91$110.99● Close Price0.00M6.43M12.87M19.30M25.73MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FOSTER JAMES CDirectorOct 22 '26Sale350.0024,0428,414,70031,596Oct 26
FOSTER JAMES CDirectorOct 22 '26Option Exercise244.4124,0425,876,10555,638Oct 26
Parisotto Shannon MCEVP, Disc & Safety AssessmentOct 21 '26Sale344.412,156742,5484,807Oct 23
Parisotto Shannon MCEVP, Disc & Safety AssessmentOct 21 '26Option Exercise244.412,156526,9486,963Oct 23
Parisotto Shannon MCEVP, Disc & Safety AssessmentOct 05 '26Option Exercise208.44981204,4805,788Oct 07
Parisotto Shannon MCEVP, Disc & Safety AssessmentOct 05 '26Sale308.44981302,5804,807Oct 07
Coleman GlennEVP & Chief Financial OfficerSep 30 '26Buy297.43102,97427,762Oct 02
FOSTER JAMES CDirectorAug 25 '26Sale300.0033,56110,068,30031,596Aug 27
FOSTER JAMES CDirectorAug 25 '26Option Exercise199.4233,5616,692,84565,157Aug 27
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 19 '26Option Exercise194.122,039395,8116,846Aug 20
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 19 '26Sale294.122,039599,7114,807Aug 20
Andrews Nancy CDirectorAug 18 '26Option Exercise164.3057394,1442,011Aug 20
Andrews Nancy CDirectorAug 18 '26Sale285.24573163,4431,438Aug 20
Girshick BirgitChief Executive OfficerAug 11 '26Option Exercise179.666,5001,167,79042,513Aug 13
Girshick BirgitChief Executive OfficerAug 11 '26Sale279.906,5001,819,35036,013Aug 13
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.